Fumitoshi Asai - Concepedia

Author

Fumitoshi Asai

Azabu University ORCID

Also Known As

F ASAI, F Asai, F. ASAI, F. Asai, FUMITOSHI ASAI, Fumitoshi ASAI, Fumitoshi Asai, Koichi FUJIMOTO

149

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Azabu University Daiichi-Sankyo (Japan)The University of Osaka Okayama University Eli Lilly (United States)

About

Fumitoshi Asai is an author at Azabu University specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	29	1.1K
2	Natural Sciences	8	8	169
3	Health Sciences	2	2	25
4	Education	1	1	17
5	Social Sciences	1	1	31

Fumitoshi Asai

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
The <i>in vivo</i> pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist properties Atsuhiro Sugidachi, Fumitoshi Asai, Taketoshi Ogawa, British Journal of Pharmacology	2000	235
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite Atsuhiro Sugidachi, Taketoshi Ogawa, Atsushi Kurihara, Journal of Thrombosis and Haemostasis Molecular PharmacologyThrombosisEfficient GenerationBiochemistryBlood Platelet	2007	218
A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y<sub>12</sub> inhibitor, compared with clopidogrel in healthy humans Joseph A. Jakubowski, Nobuko Matsushima, Fumitoshi Asai, British Journal of Clinical Pharmacology	2006	128
Antiplatelet action of R‐99224, an active metabolite of a novel thienopyridine‐type G<sub>i</sub>‐linked P2T antagonist, CS‐747 Atsuhiro Sugidachi, Fumitoshi Asai, Kenji Yoneda, British Journal of Pharmacology PharmacotherapyAdp-induced Platelet AggregationInflammationMolecular PharmacologyThrombosis	2001	110
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y<sub>12</sub> inhibitor: A single ascending dose study in healthy humans Fumitoshi Asai, Joseph A. Jakubowski, Hideo Naganuma, Platelets	2006	108
Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor Irina Algaier, Joseph A. Jakubowski, Fumitoshi Asai, Journal of Thrombosis and Haemostasis BiochemistryG Protein-coupled ReceptorMedicineHuman P2y12 ReceptorMechanism Of Action	2008	92
Distribution of periodontopathic bacterial species in dogs and their owners Yoshie Yamasaki, Ryota Nomura, Kazuhiko Nakano, Archives of Oral Biology PeriodontologyVeterinary ScienceVeterinary ResearchPeriodontopathic Bacterial SpeciesOral Microbiology	2012	73
Molecular Detection of Human Periodontal Pathogens in Oral Swab Specimens from Dogs in Japan Yukio Kato, Mitsuyuki Shirai, Masaru Murakami, Journal of Veterinary Dentistry	2011	67
Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitor Michihiro Hasegawa, Atsuhiro Sugidachi, Taketoshi Ogawa, Thrombosis and Haemostasis PharmacotherapyPlatelet AggregationExperimental PharmacologyPharmaceutical ChemistryAdp-induced Platelet Aggregation	2005	62
Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species Y. Niitsu, Atsuhiro Sugidachi, Taketoshi Ogawa, European Journal of Pharmacology ThrombopoiesisThrombosisPlatelet Aggregation InhibitorsBlood PlateletRepeat Oral Dosing	2007	47

Page 1